Medlab Clinical Limited (MDC) 2015年年度报告「ASX」.pdf

1、MEDLAB CLINICAL LIMITED(ABN 51 169 149 071)ANNUAL REPORTFOR THE PERIOD ENDED 30 JUNE 2015Copyright Medlab Clinical Ltd 2015INNOVATION-QUALITY-LIFE SCIENCESINNOVATION-QUALITY-LIFE SCIENCESCONTENTSmedlab.coINNOVATION-QUALITY-LIFE SCIENCESChairmans Letter4CEO Report5Directors Report9Auditors Independen

2、ce Declaration18Financial Statements19Directors Declaration45Independent Auditors Report46Shareholder Information48Corporate Directory50 3 medlab.coINNOVATION-QUALITY-LIFE SCIENCES 4 CHAIRMANS LETTEROn behalf of the Board of Medlab Clinical Limited(Medlab),I am pleased to present our first Annual Re

3、portas an ASX Listed company.2015 has certainly been a very exciting year and one of transition for Medlab.It was back on 13 April 2015,when we originally lodged our prospectus with the ASX and after a successful IPO,we listed on the ASX on14 July 2015.We are very proud to have completed the listing

4、 especially given the volatile state of themarket and the unfortunate demise of our original Lead Broker,BBY Limited as we were nearing completion.We are very grateful to Shaw and Partners who had belief in us and took over as Broker.We would not have been able to achieve this important milestone wi

5、thout the support of our advisors at Hall Chadwick andSparke Helmore.Medlab is a unique company as it has three distinct areas of business and subsequent intended sources of revenue:Sale of nutraceutical products developed from our research into chronic illnesses.It is anticipated that these sales w

6、ill self-fund our research.Development of pharmaceuticals that we intend to sell or licence to large multi-national companies Development of platform technologies to repurpose existing drugsChronic illness is very prevalent today and our research is targeting the development of bacteria-based medici